总的来说，魏志杰教授的研究为AML患者的治疗带来了新的希望。通过合理使用巴利昔单抗，可以显著降低aGVHD的发生率，提高患者的生活质量。如果你或你的家人正在接受造血干细胞移植治疗，不妨与医生讨论一下是否适合采用这种预处理方案。

在haplo-HCT后第+1天和第+4天预防性使用巴利昔单抗安全性良好，可显著降低CR-AML患者II-IV级aGVHD的发生率，而不会影响长期预后。其疗效在不同AML亚型间存在差异，其中M1和M4亚型患者获益最显著，而M7亚型的疗效最差。这些结果表 ...

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses ...

HSCT is also limited in efficacy, due to immune-suppressive comedications that aim at controlling GvHD: 40% of post-HSCT AML patients relapse, with a dismal prognosis of 2-year survival less than 20%.

To manage GvHD, clinicians administer immunosuppressants ... The company is set to begin a global, pivotal phase 2/3 trial with mocravimod in AML patients undergoing allogenic HSCT.

A novel regimen significantly reduced risk for moderate to severe chronic graft-versus-host disease for certain patients who ...

“Approximately 46,000 people are diagnosed with AML, ALL, and MDS in the US each ... deadly treatment-related toxicities, like GVHD," study author Everett Meyer, MD, PhD, hematologist and ...

The trial indicated that 100% of AML patients treated with INB-100 post ... and graft-versus-host disease (GvHD) in line with historical data. Dr. Joseph P. McGuirk, from The University of Kansas ...

Niktimvo was launched for chronic GVHD in late January 2025 in partnership ... Management emphasized the potential for label ...